The Dermatology Digest

FEBRUARY 20, 2025

The Phase 1b trialis a randomized, double-blind, placebo-controlled trial evaluating the safety, tolerability and pharmacokinetics of once-daily oral VYN202 in three dosing cohorts (0.25mg, 0.5mg, 1mg doses), compared to placebo, for 12 weeks in subjects with moderate-to-severe plaque psoriasis.

Safety 36

Safety Office Dermatology Treatments 36

AAAMS

JANUARY 21, 2025

Safe and Effective Procedures: Training ensures that your practitioners understand the proper techniques and safety protocols, minimizing risks and enhancing the quality of results. Enhanced Client Trust : Clients are more likely to choose a med spa where practitioners are certified, knowing their safety and satisfaction are prioritized.

Med Spa 52

Med Spa Chemical Peels Training Legal 52

The Dermatology Digest

OCTOBER 16, 2024

_Ann Haas, MD, and Jerome Potozkin, MD, are being honored with the Patient Safety Hero Award for their efforts on behalf of the California Society of Dermatology and Dermatologic Surgery to protect physicians’ ability to mix and dilute drugs in-office. ASDSA is proud to name them as 2024 Patient Safety Hero Awardees.”

Safety 36

Safety Surgery Office Dermatology 36

Lipgloss and Aftershave

NOVEMBER 1, 2024

Active Ingredients in Pigmentation Therapy In-office treatments are complemented by topical agents that help maintain results and prevent new pigmentation. These are some topical agents to enhance in-office treatments, maintaining and prolonging results through consistent home care.

Chemical Peels 52

Chemical Peels Hyperpigmentation Vitamin C Microneedling 52

The Dermatology Digest

MARCH 17, 2025

The overall safety profile of povorcitinib is consistent with previous data. No new safety signals were observed and both doses were well tolerated. Both studies include a 12-week double-blind, placebo-controlled treatment period, followed by a 42-week extension period and 30-day safety follow-up. 75mg: 40.6% 75mg: 42.3%

Safety 36

Safety Document Therapy Clinic 36

The Dermatology Digest

JUNE 5, 2024

Check out TDD’s one-on-one interview with Iain Stuart, PhD , Chief Scientific Officer at Vyne Therapeutics. The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks.

Safety 73

Safety Office Facials Therapy 73

The Dermatology Digest

JANUARY 22, 2025

We are excited to partner with Revance to further clinical development of our unique program, using our Xyngari product for a needle-free, intradermal delivery of a botulinum toxin, like Daxxify, to the dermis, says Gerald Proehl, Chairman, President, and Chief Executive Officer of Dermata, in a news release.

Injections 36

Injections Office Partnerships Clinic 36

The Dermatology Digest

NOVEMBER 6, 2024

. “The new Translational Bridge Award addresses a critical gap in lupus research, enabling scientists to bring their most promising ideas closer to people living with lupus,” says Teodora Staeva, PhD, LRA Vice President and Chief Scientific Officer, in a news release.

Hospital 36

Hospital Therapy Management Networking 36

The Dermatology Digest

APRIL 11, 2025

In the multicenter, open-label, 12-week, Phase 2 study evaluating the safety and efficacy of QTORIN rapamycin for microcystic LMs, 100% of participants were either “Very Much Improved (41.7%) or Much Improved (58.3%) as rated by the Clinician Global Impression of Change (CGI-C), a 7-point change scale conducted by live clinician assessment.

Therapy 36

Therapy Dermatology Office Clinic 36

The Dermatology Digest

MARCH 5, 2025

This is a great milestone for our team, as we continue to examine the acne market, we believe there is still a high unmet need by patients for an acne product like XYNGARI, says Gerry Proehl, Dermatas Chairman, President, and Chief Executive Officer, in a news release.

Treatments 36

Treatments Rosacea Pores Office 36

The Dermatology Digest

JANUARY 20, 2024

The study is designed to assess the safety, tolerability, and pharmacokinetics, of orally administered EVO756. The Phase 1 study is a randomized, double-blind, placebo-controlled single and multiple ascending dose (SAD and MAD) study in normal healthy adults and an open-label study in adults with CSU.

Safety 74

Safety Office Dermatitis Clinic 74

The Dermatology Digest

JULY 16, 2024

Whether it’s your first visit to the city or an annual tradition, SHADES at Edge offers a fresh, imaginative way to take in the 360 views of our iconic skyline like never before,” says Francesca Merlino, Chief Commercial Officer at Hudson Yards Experiences, in a news release.

Sun Protection 74

Sun Protection Partnerships Office Safety 74

The Dermatology Digest

MARCH 18, 2024

The Phase 3 clinical trials achieved all co-primary and secondary endpoints, and subjects completed the 16-week treatment with no significant safety issues.

Rosacea 74

Rosacea Medical Office Clinic 74

The Dermatology Digest

FEBRUARY 10, 2025

Proof-of-concept efficacy and safety data from a Phase 1b study of rezpegaldesleukin in AD patients were presented at the 2023 European Academy of Dermatology and Venereology Congress. Senior Vice President and Chief Research & Development Officer at Nektar, in a news release.

Dermatitis 36

Dermatitis Therapy Office Safety 36

The Dermatology Digest

MARCH 14, 2025

Novartis is the ideal partner to help us in this mission due to their unparalleled expertise in innovative medicines and their dedication to improving health outcomes,” adds Chief Medical Officer at the NFL, Dr. Allen Sills.

Pharmaceutical 36

Pharmaceutical Partnerships Medical Office 36

The Dermatology Digest

JANUARY 29, 2024

The STudy of Roflumilast foam Applied Topically for the redUction of seborrheic derMatitis (STRATUM) was a parallel group, double-blind, vehicle-controlled study evaluating the safety and efficacy of Zoryve (roflumilast) foam, 0.3% Zoryve foam was well-tolerated with a favorable safety and tolerability profile.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

The Dermatology Digest

FEBRUARY 11, 2025

This is based on the continued emergence of bempikibart data in alopecia areata patients with longer-term follow-up from Part A of the SIGNAL-AA Phase 2a clinical trial, the robust pharmacologic data, and a well-tolerated safety profile,” says Jodie Morrison, Chief Executive Officer of Q32 Bio, in a news release.

Clinic 36

Clinic Therapy Office Tools 36

The Dermatology Digest

FEBRUARY 14, 2024

The prevalence of atopic dermatitis, an extremely burdensome skin condition, continues to grow, and there is an increasing need for new, long-term, treatment options, especially for children,” says Todd Zavodnick, Chief Executive Officer of Dermavant, in a news release.

Dermatitis 74

Dermatitis Office Management Eczema 74

The Dermatology Digest

SEPTEMBER 20, 2024

Secondary efficacy objectives include progression-free survival, overall survival and local control up to twelve months after treatment, and the safety objective is the measurement of any related adverse events. Dr. Robert B.

Office 74

Office Clinic Safety Medical 74

The Dermatology Digest

MAY 16, 2024

Sonelokimab in PsA For PsA, Phase 3 initiation is anticipated in Q4 2024 following the announcement in March 2024 of the full dataset from the global Phase 2 ARGO trial (M1095-PSA-201) evaluating the efficacy and safety of the Nanobody sonelokimab over 24 weeks in patients with active PsA.

Safety 68

Safety Clinic Dermatology Office 68

The Dermatology Digest

JANUARY 14, 2024

Zoryve foam was well-tolerated with a favorable safety and tolerability profile. As the first topical drug approved with a new mechanism of action for this condition in 20 years, foam represents an important advancement in treatment and addresses a truly significant need in this population.”

Dermatitis 72

Dermatitis Office Dermatology Safety 72

The Dermatology Digest

FEBRUARY 26, 2024

“The favorable response from both the FDA and EMA aligns with the strengths we have consistently highlighted in our trial programs and outlines a clear regulatory path for sonelokimab in hidradenitis suppurativa” says Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, in a news release.“

Office 74

Office Clinic Innovations Safety 74

Natural Beauty Med Spa

JANUARY 4, 2025

Lets talk about why you can be confident in the safety of this treatment. CO2Lift treatment is a type of carboxytherapy, which has been around for years and has a sterling record of safety for patients of virtually all skin types. But did you know that CO2 can actually provide amazing results as part of a skincare treatment?

Med Spa 52

Med Spa Treatments Chemical Peels Skin Types 52

North Dallas Dermatology Associates

NOVEMBER 1, 2023

One misconception is cosmetic procedures are the same everywhere, from a local spa to a board-certified physician’s office. Safety Concerns and Potential Adverse Effects Another crucial consideration in evaluating where to have your cosmetic procedure performed is the ability to manage potential adverse effects.

Office 36

Office Safety Medical Training 36

Les Nouvelles Esthetics & Spa

JANUARY 31, 2024

An interview with Lauren Becotte Rampello Lauren Becotte Rampello is the Founder and Chief Creative Officer of Pure Glow, premium airbrush tanning that mimics the skin’s natural tan. We invest heavily in their training, focusing on the intricacies of our products and safety protocols. What is your plan for company growth?

Branding 78

Branding Sales Office Safety 78

The Dermatology Digest

JULY 29, 2024

Key secondary endpoints will include PASI 90, PASI 100 and sPGA 0 measured at Weeks 16 and 24, and safety and tolerability. Patients completing Week 24 will have the opportunity to participate in a long-term extension (LTE) trial, ONWARD3, that will evaluate durability and maintenance of response and long-term safety.

Clinic 36

Clinic Safety Office Treatments 36

The Dermatology Digest

SEPTEMBER 12, 2024

“The positive pivotal data from this study reinforce the potential of Dupixent to offer a new treatment option for the many people suffering from chronic spontaneous urticaria who do not respond to standard-of-care antihistamines,” says Dietmar Berger, MD, PhD, Chief Medical Officer, Global Head of Development at Sanofi, in a news release.

Safety 36

Safety Office Medical Dermatology 36

Natural Beauty Med Spa

APRIL 28, 2024

However, you might be reluctant to commit to it due to concerns about safety. Safety is of the utmost importance to us, and we take every reasonable precaution to protect our patients. If you would like to learn more about us and how we may be able to help you look and feel amazing, contact our Dearborn office at 312-981-1291.

Med Spa 52

Med Spa Scarring Safety Makeup 52

The Beauty Brains

MARCH 4, 2019

They also have advice from a body called the scientific committee for cosmetic safety or SCCS, which is composed largely of academics with an interest in medicine and general science. But the most significant way that cosmetic product safety is addressed is through the requirement for safety assessments. Smaller producers?

Safety 52

Safety Cosmetic Products Pharmaceutical Ingredients 52

The Dermatology Digest

JANUARY 5, 2024

“Verrica’s VP-315 program is designed to provide for the targeted delivery of an oncolytic peptide engineered to stimulate the patient’s immune system and destroy cancer cells,” says Ted White, Verrica’s President and Chief Executive Officer, in a news release.

Pharmaceutical 36

Pharmaceutical Safety Office Clinic 36

The Dermatology Digest

APRIL 18, 2024

The safety profile was similar across all three arms and overall, 88.9% of adverse events were rated as mild and no serious adverse events were identified. The study appears in the Aesthetic Surgery Journa l. “The The study appears in the Aesthetic Surgery Journa l.

Safety 36

Safety Office Surgery Dermatology 36

The Dermatology Digest

JUNE 10, 2024

With patients experiencing AK over larger surface areas, dermatologists are looking for ways to treat the entire affected area to help prevent further lesion progression,” saysKarl Ziegelbauer, Chief Scientific Officer at Almirall, in a news release.

Treatments 36

Treatments Safety Office Clinic 36

The Dermatology Digest

FEBRUARY 22, 2024

The primary endpoints of the study are the proportion of SK lesions with a Physician Lesion Assessment (PLA) score of clear (PLA=0) at last visit and the safety of SM-020 gel 1.0% CT-213 is a Phase 2b randomized, double-blind, vehicle-controlled clinical trial in 60 subjects with five to ten SK target lesions treated with SM-020 gel 1.0%

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

FEBRUARY 22, 2024

The primary endpoints of the study are the proportion of SK lesions with a Physician Lesion Assessment (PLA) score of clear (PLA=0) at last visit and the safety of SM-020 gel 1.0% CT-213 is a Phase 2b randomized, double-blind, vehicle-controlled clinical trial in 60 subjects with five to ten SK target lesions treated with SM-020 gel 1.0%

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

DECEMBER 14, 2023

Patients returned at week 16 to assess safety and evaluate maintenance response. Additionally, it can increase the time of use for biologics instead of switching between agents; therefore, decreasing overall healthcare costs and burden on patients and physician offices.” At week 12, patients stopped using the cream.

Injections 36

Injections Safety Office Therapy 36

The Dermatology Digest

JULY 22, 2024

“We are delighted at the launch of Uzpruvo in Europe and to be first-to-market,” adds Robert Wessman, Chief Executive Officer of Alvotech. This launch symbolizes the robustness of our platform, the value of our partnership with STADA, and our collective focus on the importance of biosimilars.”

Partnerships 36

Partnerships Pharmaceutical Marketing Office 36

The Dermatology Digest

JANUARY 5, 2024

“Based on the data seen in our pivotal trials, DFD-29 could fundamentally improve the treatment paradigm for patients suffering from both inflammatory lesions and erythema (redness) from rosacea,” says Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical, in a news release.

Rosacea 36

Rosacea Medical Office Clinic 36